Stop Doing That: A Guide to Breaking Bad Habits
- A major clinical trial, the SELECT trial, has revealed a potential increased risk of cardiovascular events - including heart attack, stroke, and cardiovascular death - in individuals with...
- The SELECT trial followed participants for an average of 3.4 years.
- The SELECT trial focused on adults with obesity (BMI of 30 or higher) *and* pre-existing cardiovascular disease, such as a history of heart attack, stroke, or peripheral artery...
Ozempic and Cardiovascular Risk: New Findings Demand Closer Scrutiny
Table of Contents
What happened? A Closer Look at teh SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of cardiovascular events – including heart attack, stroke, and cardiovascular death – in individuals with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic). The study, involving over 17,600 participants, showed a statistically meaningful, though relatively small, increase in these events compared to a placebo group. This finding challenges previous assumptions about the cardiovascular safety of GLP-1 receptor agonists like semaglutide.
Key Findings and Data Breakdown
The SELECT trial followed participants for an average of 3.4 years. the primary composite outcome of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke occurred in 6.5% of those receiving semaglutide versus 5.8% in the placebo group – a hazard ratio of 1.13.While this difference is statistically significant, it’s crucial to understand the absolute risk increase. Specifically, this translates to approximately 1.1 additional cardiovascular events per 100 person-years of treatment.
| Outcome | Semaglutide Group (%) | Placebo Group (%) | Hazard Ratio |
|---|---|---|---|
| Cardiovascular Death | 1.5 | 1.2 | 1.26 |
| Nonfatal Myocardial Infarction | 3.7 | 3.3 | 1.12 |
| Nonfatal Stroke | 1.9 | 1.3 | 1.47 |
| Composite Outcome (CV Death, MI, Stroke) | 6.5 | 5.8 | 1.13 |
Who is Affected? Understanding the Patient Population
The SELECT trial focused on adults with obesity (BMI of 30 or higher) *and* pre-existing cardiovascular disease, such as a history of heart attack, stroke, or peripheral artery disease. This is a critical distinction. The findings do *not* necessarily apply to individuals with obesity who do not have established cardiovascular issues, or to those using semaglutide for type 2 diabetes. The average age of participants was 61, and approximately 40% were women.
What Dose This Meen? Implications for Patients and Physicians
These results necessitate a more cautious approach to prescribing semaglutide, and similar GLP-1 receptor agonists, for patients with pre-existing cardiovascular disease.Doctors should carefully weigh the potential benefits of weight loss against the newly identified cardiovascular risks. A thorough discussion with patients about these risks is paramount, ensuring informed consent and shared decision-making.Further research is needed to determine if these findings extend to other GLP-1 receptor agonists and to different patient populations.
Timeline of events
- November 2